- Home
- KBON vs ALT Comparison
KBON vs ALT Comparison
Compare KBON & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
HOLD
Current Price
$3.39
Company Overview
Basic Information| Metric | KBON | ALT |
|---|---|---|
| Founded | 2025 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 442.4M | 415.3M |
| IPO Year | N/A | 2005 |
Fundamental Metrics
Financial Performance| Metric | KBON | ALT |
|---|---|---|
| Price | $10.05 | $3.39 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 30.5K | ★ 2.9M |
| Earning Date | 01-01-0001 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $756,308.50 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $10.04 | $2.91 |
| 52 Week High | $10.15 | $7.73 |
Technical Indicators
Market Signals| Indicator | KBON | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 45.28 | 32.86 |
| Support Level | $10.05 | $2.91 |
| Resistance Level | $10.11 | $4.25 |
| Average True Range (ATR) | 0.02 | 0.23 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 0.00 | 1.80 |
Price Performance
Historical Comparison KBON
ALT
About KBON Karbon Capital Partners Corp. Class A Ordinary Shares
Karbon Capital Partners Corp is a blank check company.
About ALT Altimmune Inc.
Altimmune Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity, metabolic diseases, and liver diseases. Its product candidate, pemvidutide (formerly known as ALT-801), is a novel, investigational, peptide-based GLP-1/glucagon dual receptor agonist. Pemvidutide is currently in clinical development for obesity and metabolic-associated steatohepatitis (MASH). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.